A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won't be able to afford the medication. Zurzuvae (zuranolone) was first approved by the U.S. Food and Drug...
A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won't be able to afford the medication.
Despite Zurzuvae's high cost, drugmaker Sage Therapeutics said Tuesday that the drug should hit the market by December, and that it and partner Biogen are now talking with insurers about coverage of the medication. Mental health experts have welcomed the drug's approval, not just because it presents a new way to treat postpartum depression but also because it “appears to be fast-acting,” Dr. Catherine Monk, chief of the Division of Women’s Mental Health in the Department of Obstetrics and Gynecology at the Columbia University Vagelos College of Physicians and Surgeons in New York City, told CNN.
“It remains to be seen how much insurance companies will cover it or if they will require women to ‘fail’ treatment with less expensive SSRIs before paying for this new treatment,” Furey said. “I hope that is not the case and that its price will not be a barrier to accessing this treatment.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New postpartum depression drug gets almost $16,000 price tag, raising questions about accessA newly approved medication to treat postpartum depression will cost $15,900 per 14-day course, before insurance, when it reaches the market later this year, raising concerns among doctors and researchers that some patients may have trouble paying for the drug.
Read more »
Biogen quarterly results top estimates despite complex Alzheimer's drug launchCompany focuses on new products in Alzheimer’s, postpartum depression as multiple sclerosis product revenues decline
Read more »
New weight loss drug: FDA approves Zepbound, a version of diabetes drug Mounjaro for obesityZepbound, a new version of the popular diabetes treatment Mounjaro, can now be sold as a weight-loss drug and helped patients lose 25% of their weight.
Read more »
Historic drug bust: 3 charged in drug trafficking operation at home where kids were livingAt least three people in Massachusetts were arrested in what is being described as a historic drug bust, authorities announced on Monday.
Read more »
SiriusXM has a new app, a new logo, and new audience to conquerSiriusXM debuted a new app and logo. The app integrates Pandora, podcast offerings like Conan and Stitcher, and traditional satellite radio. It’ll work on mobile and connect to the car.
Read more »
New San Diego library master plan calls for new branches, new priorities, more equityNew blueprint replaces 2002 plan that spurred 84 percent facilities expansion; council also wants more money for operations
Read more »